2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Klatskin Tumor
2
Cholangiocarcinoma
2
Sarcoma, Kaposi
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Liver Neoplasms
1
Epstein-Barr Virus Infections
1
Carcinoma, Hepatocellular
1
Acquired Immunodeficiency Syndrome
1
Interventions
Doxorubicin
10
Zidovudine
9
Vincristine
7
Bleomycin
7
Nivolumab
6
Liposomes
5
Interferon alpha-2
5
Etoposide
5
tecogalan
4
pembrolizumab
4
liposomal doxorubicin
4
Valganciclovir
4
Specimen Handling
4
Semaxinib
4
Paclitaxel
4
Nelfinavir
4
Magnetic Resonance Spectroscopy
4
pomalidomide
3
Ritonavir
3
Filgrastim
3
Biopsy
3
Bevacizumab
3
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
2
sargramostim
2
interferon alfa-n1
2
Propranolol
2
Indinavir
2
Docetaxel
2
Didanosine
2
Daunorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Kaposi
×
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
×
Clear all
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn